- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/525 - Tumour necrosis factor [TNF]
Patent holdings for IPC class C07K 14/525
Total number of patents in this class: 733
10-year publication summary
|
62
|
81
|
54
|
67
|
51
|
51
|
60
|
40
|
40
|
15
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1281 |
23 |
| Apogenix AG | 68 |
19 |
| Universiteit Gent | 1371 |
18 |
| Vib VZW | 888 |
18 |
| Philogen S.p.A. | 126 |
15 |
| Universitat Stuttgart | 271 |
14 |
| Shattuck Labs, Inc. | 123 |
14 |
| Centre National de La Recherche Scientifique | 10886 |
12 |
| The General Hospital Corporation | 4827 |
12 |
| Centre hospitalier Regional universitaire de Montpellier | 31 |
12 |
| UCB Biopharma SRL | 596 |
11 |
| Cedars-Sinai Medical Center | 1189 |
10 |
| Sanofi Aatd Inc. | 17 |
10 |
| Hoffmann-La Roche Inc. | 3699 |
8 |
| The Trustees of the University of Pennsylvania | 4406 |
8 |
| Apeptico Forschung und Entwicklung GmbH | 35 |
8 |
| Memed Diagnostics Ltd. | 80 |
8 |
| Thomas Jefferson University | 548 |
8 |
| Universite de Montpellier | 1029 |
8 |
| Orionis Biosciences BV | 76 |
8 |
| Other owners | 489 |